Screener
Ionis Pharmaceuticals IONS Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance.
The source filing: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2026
- Accession
- 0000874015-26-000115
| Foreign tax effects | (118) | 0.0% | % |
| Effect of cross-border tax laws | 459 | (0.1 | )% |
| Changes in unrecognized tax benefits | 12,145 | (3.2 | )% |
| Changes in valuation allowances | 93,773 | (24.7 | )% |
| Tax credits: | |||
| Research and development tax credits | (17,754) | 4.7% | % |
| Orphan drug tax credits | (30,521) | 8.0% | % |
| Non-taxable or non-deductible items: |
Item 15. Exhibits and Financial Statement Schedules
FAQ
- What is Ionis Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount?
- Ionis Pharmaceuticals (IONS) reported effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount of $23.44M in Q4 2025.
- How has Ionis Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount changed year-over-year?
- Ionis Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount decreased by 38.5% year-over-year, from $38.15M to $23.44M.
- What is the long-term trend for Ionis Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount has grown at a -26.9% compound annual growth rate (CAGR), from $175.39M to $93.77M.
- What does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount mean?
- This represents the adjustment to the valuation allowance for deferred tax assets, reflecting changes in management's assessment of the likelihood that these assets will be realized. A significant change often indicates shifts in future profitability expectations or tax planning strategies.
Ask your AI about Ionis Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude